Table 22Mid potency statin in combination with fibrate as compared to high potency statin monotherapy among patients with CHD: strength of evidence domains and summary of key findings

OutcomeNo. Studies
(N)
Risk of BiasDirectnessConsistencyPrecisionReporting Bias

Other Issues
Findings and Magnitude of EffectStrength of Evidence
Long-Term Benefits and Serious Adverse Events
MortalityNoneN/AN/ANANANA

NA
No eligible studiesInsufficient
Acute Coronary EventsNoneNANANANANA

NA
No eligible studiesInsufficient
Revascularization ProceduresNoneNANANANANA

NA
No eligible studiesInsufficient
Serious Adverse EventsNoneNANANANANA

NA
No eligible studiesInsufficient
Surrogate Clinical Outcomes
LDL-c1
(102)
High

[Jadad<3]
Direct

[Measured]
N/AImpreciseNone detected

None
Monotherapy lowered LDL-c by 1% to 14% percent more than combination therapyInsufficient
HDL-c1
(102)
High

[Jadad<3]
Direct

[Measured]
N/AImpreciseNone detected

None
Combination therapy raised HDL-c by 4% to 24% more than atorvastatin monotherapyInsufficient

CHD = coronary heart disease; NA = not applicable

From: Results

Cover of Combination Therapy Versus Intensification of Statin Monotherapy: An Update
Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet].
Comparative Effectiveness Reviews, No. 132.
Monroe AK, Gudzune KA, Sharma R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.